Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 17/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5066799 | 0.82 | SHMT2 (0.35) | FFAR1KDM4EMAPTHTTSMN1; SMN2 | |
| SCHEMBL14457466 | 0.75 | AGXT (0.36) | KDM4EMAPTHTTSMN1; SMN2SHMT2 | |
| SCHEMBL4309675 | 0.74 | AGXT (0.37) | SHMT2 | |
| SCHEMBL4304709 | 0.73 | KDM4E (0.50) | FFAR1KDM4EMEN1KMT2A | |
| SCHEMBL4305889 | 0.71 | AGXT (0.34) | MAPTSHMT2 | |
| SCHEMBL4305125 | 0.71 | PDE10A (0.44) | SHMT2 | |
| SCHEMBL15212315 | 0.71 | AGXT (0.48) | KDM4EMAPTSMN1; SMN2L3MBTL1SHMT2 | |
| SCHEMBL15220956 | 0.71 | AGXT (0.48) | KDM4EMAPTSMN1; SMN2L3MBTL1SHMT2 | |
| SCHEMBL4311415 | 0.70 | PDE10A (0.37) | — | |
| SCHEMBL14457590 | 0.70 | AGXT (0.34) | SHMT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090044345-A1 | Use of Metal Complex Compounds as Oxidation Catalysts | CIBA CORP. | 2009-02-19 | — | — | US | disclosed |
| US-20090044345-A1 | Use of Metal Complex Compounds as Oxidation Catalysts | CIBA CORP. | 2009-02-19 | — | — | US | disclosed |
| US-20090044345-A1 | Use of Metal Complex Compounds as Oxidation Catalysts | CIBA CORP. | 2009-02-19 | — | — | US | disclosed |
| EP-1981635-A1 | USE OF METAL COMPLEX COMPOUNDS AS OXIDATION CATALYSTS | Ciba Holding Inc. (CH) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007090461-A1 | USE OF METAL COMPLEX COMPOUNDS AS OXIDATION CATALYSTS | CIBA HOLDING INC. (CH) | 2007-08-16 | — | — | WO | disclosed |
| WO-2007090461-A1 | USE OF METAL COMPLEX COMPOUNDS AS OXIDATION CATALYSTS | CIBA HOLDING INC. (CH) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090044345-A1 | Use of Metal Complex Compounds as Oxidation Catalysts | MT-CO2, MT-CO1, SOD1 | FFAR1 4606/4885KDM4E 3219/4885MAPT 1558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.